Panacos Pharmaceuticals, Inc.

Panacos Pharmaceuticals, Inc.

Panacos Pharmaceuticals, Inc. (Panacos) is a development-stage biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.

Contact Details

Office Address

Panacos Pharmaceuticals, Inc.
P.O. Box 95009
Newton, MA, USA 02495
Phone: (617) 926-1551
Fax: (617) 923-2245

Executives

Chairman

Jeremy Hayward-Surry

President, CEO, and Director

Alan W. Dunton

Business Reviews for Panacos Pharmaceuticals, Inc.

Related Companies